Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Reddit leads social media platforms in revenue growth per user
- L3Harris CEO steps down amid conduct review, shares drop
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- US considers new sanctions on Brazilian judge, FT reports
- Six dead in 'stampede-like' incident at India temple, ANI says
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
February 12, 2026 8:00 AM ESTAchieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024
Attained GAAP and non-GAAP Profitability for Full Year 2025, with Sustainable Growth in Operating Income Expected
Launched Alnylam 2030 Strategy Focused on Scaling Alnylam through Durable ATTR Leadership, Long-Term Sustainable Innovation, and Exceptional Financial Results
Announced 2026 Pipeline Goals, Including 4 Clinical Readouts, 3 Ongoing Pivotal Studies, 3 Phase 2 Study Initiations, and 3+ New IND Filings
Reiterates Net Product Sales Guidance and Provides Additional 2026 Financial Guidance
... More
